Implementation of Cardiometabolic Centers and Training Programs
- PMID: 35316465
- DOI: 10.1007/s11892-022-01459-y
Implementation of Cardiometabolic Centers and Training Programs
Abstract
Purpose of review: Type 2 diabetes is frequently accompanied by obesity, nonalcoholic fatty liver disease, chronic kidney disease, and cardiovascular disease, which collectively contribute to the high burden of cardiometabolic disease. This review discusses cardiometabolic disease management, strategies to implement cardiometabolic centers to deliver care, and dedicated programs to train the next generation of cardiometabolic experts.
Recent findings: Sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid receptor antagonist have demonstrated beneficial effects across cardiometabolic conditions. However, utilization of effective pharmacotherapies is low in clinical practice, in part due to clinical inertia and traditional sharp delineation in clinical responsibilities of specialists. Multidisciplinary clinics and population-health models can provide comprehensive care but require investment in physical and information technology infrastructure as well as in training and accreditation. Post-internal medicine residency cardiometabolic health training programs have been proposed. Implementing cardiometabolic centers in health systems involves reshaping current practices. Training programs focused on cardiometabolic health are needed to address the growing burden of disease and specific training needs in this ever-expanding area.
Keywords: Cardiometabolic disease; Cardiovascular disease; Care delivery models; Diabetes; Medical training.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.J Cardiovasc Pharmacol Ther. 2022 Jan-Dec;27:10742484221146371. doi: 10.1177/10742484221146371. J Cardiovasc Pharmacol Ther. 2022. PMID: 36546652 Review.
-
Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration.Curr Diab Rep. 2019 Dec 4;19(12):157. doi: 10.1007/s11892-019-1260-0. Curr Diab Rep. 2019. PMID: 31802265 Review.
-
JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk.J Clin Lipidol. 2022 Mar-Apr;16(2):115-127. doi: 10.1016/j.jacl.2022.03.007. J Clin Lipidol. 2022. PMID: 35430025
-
Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease.Clin Physiol Funct Imaging. 2019 Mar;39(2):122-127. doi: 10.1111/cpf.12526. Epub 2018 May 29. Clin Physiol Funct Imaging. 2019. PMID: 29808958
-
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!Metabolism. 2019 Dec;101:154001. doi: 10.1016/j.metabol.2019.154001. Epub 2019 Oct 28. Metabolism. 2019. PMID: 31672448 Review.
Cited by
-
Obesity and Atherosclerotic Cardiovascular Disease: A Review of Social and Biobehavioral Pathways.Methodist Debakey Cardiovasc J. 2025 Feb 18;21(2):23-34. doi: 10.14797/mdcvj.1528. eCollection 2025. Methodist Debakey Cardiovasc J. 2025. PMID: 39990759 Free PMC article. Review.
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
-
- National Diabetes Statistics Report, 2020 | CDC. https://www.cdc.gov/diabetes/data/statistics-report/index.html . Accessed 1 Aug 2021
-
- Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metrics. 2010;8:29. https://doi.org/10.1186/1478-7954-8-29 . - DOI
-
- Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407–18. https://doi.org/10.1056/NEJMOA1608664 . - DOI - PubMed
-
- Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91. https://doi.org/10.1056/NEJMOA0706245 . - DOI - PubMed
-
- Fang M, Selvin E. Thirty-year trends in complications in U.S. adults with newly diagnosed type 2 diabetes. Diabetes Care. 2021;44:699–706. https://doi.org/10.2337/DC20-2304 . - DOI - PubMed - PMC
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials